{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:28:18Z","timestamp":1788323298854,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer remains a significant challenge to diagnose and treat, with considerable regional variation in management and outcomes. This study aimed to evaluate real-world outcomes of patients receiving adjuvant treatment for pancreatic cancer at a single centre in Northwest England over an 11-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected retrospectively on all patients who underwent surgery for pancreatic ductal adenocarcinoma between 2009 and 2020. Collected data included patient demographics, surgical details and adjuvant treatment received, including number of chemotherapy cycles and dose reductions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      30-day\/inpatient mortality was low (2.4%). Adjuvant chemotherapy delivery rates were high (82%) with 67.4% of patients completing the intended number of cycles. There was no additional survival benefit for patients who started chemotherapy within 8 weeks post-surgery compared to those who began later. Dose reductions did not impact survival, provided patients completed the full course of treatment (mOS 27.5 months vs. 28.5 months; HR 1.14, 95% CI 0.76\u20131.70\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.513). Following centralisation of care, a greater proportion of patients commenced adjuvant treatment (86% vs 69%\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A high proportion of patients received adjuvant treatment, with a centralised clinic model leading to increased rates of adjuvant chemotherapy delivery. Completion of the full chemotherapy course was more critical than dose intensity. Larger prospective studies are needed to investigate the factors contributing to regional variations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03341-0","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:30:54Z","timestamp":1772019054000},"page":"1183-1189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service"],"prefix":"10.1038","volume":"134","author":[{"given":"Jessica","family":"Hale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn","family":"Stott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ghaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5471-4178","authenticated-orcid":false,"given":"Christopher","family":"Halloran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusola","family":"Faluyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-7399","authenticated-orcid":false,"given":"John P.","family":"Neoptolemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7147-5703","authenticated-orcid":false,"given":"Daniel","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"3341_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3341_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld C, Ferrone CR, Katz MHG, Philip PA, Hong TS, Hackert T, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20:318\u201337.","journal-title":"Nat Rev Clin Oncol"},{"key":"3341_CR3","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3341_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10353-023-00814-x","volume":"56","author":"JP Neoptolemos","year":"2024","unstructured":"Neoptolemos JP, Hu K, Bailey P, Springfeld C, Cai B, Miao Y, et al. Personalized treatment in localized pancreatic cancer. Eur Surg. 2024;56:93\u2013109. https:\/\/doi.org\/10.1007\/s10353-023-00814-x.","journal-title":"Eur Surg"},{"key":"3341_CR5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073\u201381.","journal-title":"JAMA"},{"key":"3341_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, Hartman J, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473\u201381.","journal-title":"JAMA"},{"key":"3341_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn J, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200\u201310.","journal-title":"N Engl J Med"},{"key":"3341_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli E, Valle J, Halloran C, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet"},{"key":"3341_CR9","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Abdelghani M, Wei A, Raoul JL, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"3341_CR10","doi-asserted-by":"crossref","unstructured":"Azoulay L. Rationale, strengths, and limitations of real-world evidence in oncology: a canadian review and perspective. Oncologist. 2022;27:e731\u2013e8.","DOI":"10.1093\/oncolo\/oyac114"},{"key":"3341_CR11","doi-asserted-by":"crossref","unstructured":"Chamberlain C, Owen-Smith A, Donovan J, Hollingworth W. A systematic review of geographical variation in access to chemotherapy. BMC Cancer. 2015;16:1.","DOI":"10.1186\/s12885-015-2026-y"},{"key":"3341_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.pan.2020.01.012","volume":"20","author":"A Exarchakou","year":"2020","unstructured":"Exarchakou A, Papacleovoulou G, Rous B, Magadi W, Rachet B, Neoptolemos JP, et al. Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: a population-based study. Pancreatology. 2020;20:454\u201361. https:\/\/doi.org\/10.1016\/j.pan.2020.01.012.","journal-title":"Pancreatology"},{"key":"3341_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"3341_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"3341_CR15","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710\u20139.","journal-title":"J Clin Oncol"},{"key":"3341_CR16","unstructured":"Pancreatic Cancer UK. Variation in pancreatic cancer care and treatment. 2020. https:\/\/www.pancreaticcancer.org.uk\/wp-content\/uploads\/2020\/10\/PCUK-Variation-Report-Aug-2020.pdf"},{"key":"3341_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/gutjnl-2017-314828","volume":"68","author":"L Huang","year":"2019","unstructured":"Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, Van der Geest L, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2019;68:130\u20139.","journal-title":"Gut"},{"key":"3341_CR18","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1097\/AS9.0000000000000198","volume":"3","author":"CM Halloran","year":"2022","unstructured":"Halloran CM, Neoptolemos JP, Jackson R, Platt K, Psarelli E, Reddy S, et al. A multicenter, randomized, double-blinded, clinical trial comparing Cattell-Warren and Blumgart anastomoses following partial pancreatoduodenectomy: PANasta trial. Ann Surg Open. 2022;3:e198.","journal-title":"Ann Surg Open"},{"key":"3341_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/bjs\/znaa146","volume":"108","author":"AEJ Latenstein","year":"2021","unstructured":"Latenstein AEJ, Mackay TM, van der Geest LGM, Van Eijck CHJ, de Meijer VE, Stommel MWJ, et al. Effect of centralization and regionalization of pancreatic surgery on resection rates and survival. Br J Surg. 2021;108:826\u201333.","journal-title":"Br J Surg"},{"key":"3341_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/bjc.2016.406","volume":"116","author":"OO Faluyi","year":"2017","unstructured":"Faluyi OO, Connor JL, Chatterjee M, Ikin C, Wong H, Palmer DH. Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. Br J Cancer. 2017;116:424\u201331.","journal-title":"Br J Cancer"},{"key":"3341_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.14309\/ajg.0000000000001046","volume":"116","author":"S Han","year":"2021","unstructured":"Han S, Kolb JM, Hosokawa P, Friedman C, Fox C, Scott FI, et al. The volume-outcome effect calls for centralization of care in esophageal adenocarcinoma: results from a large national cancer registry. Off J Am Coll Gastroenterol. 2021;116:811\u20135.","journal-title":"Off J Am Coll Gastroenterol"},{"key":"3341_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/bjs.10640","volume":"105","author":"SR Markar","year":"2018","unstructured":"Markar SR, Mackenzie H, Wiggins T, Askari A, Karthikesalingam A, Faiz O, et al. Influence of national centralization of oesophagogastric cancer on management and clinical outcome from emergency upper gastrointestinal conditions. Br J Surg. 2018;105:113\u201320. https:\/\/doi.org\/10.1002\/bjs.10640.","journal-title":"Br J Surg"},{"key":"3341_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.annonc.2024.01.009","volume":"35","author":"A Napolitano","year":"2024","unstructured":"Napolitano A, Thway K, Huang P, Jones RL. Centralisation of care improves overall survival for sarcoma patients. Ann Oncol. 2024;35:338\u20139.","journal-title":"Ann Oncol"},{"key":"3341_CR24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.surg.2019.03.025","volume":"166","author":"Y Song","year":"2019","unstructured":"Song Y, Tieniber AD, Roses RE, Fraker DL, Kelz RR, Karakousis GC. National trends in centralization and perioperative outcomes of complex operations for cancer. Surgery. 2019;166:800\u201311.","journal-title":"Surgery"},{"key":"3341_CR25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","volume":"32","author":"JW Valle","year":"2014","unstructured":"Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JPN, Ghaneh P, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504\u201312.","journal-title":"J Clin Oncol"},{"key":"3341_CR26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdr561","volume":"23","author":"JL Humphris","year":"2012","unstructured":"Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713\u201322.","journal-title":"Ann Oncol"},{"key":"3341_CR27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","volume":"154","author":"RP Jones","year":"2019","unstructured":"Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, et al. European Study Group for Pancreatic Cancer. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154:1038\u201348. https:\/\/doi.org\/10.1001\/jamasurg.2019.3337.","journal-title":"JAMA Surg"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03341-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03341-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03341-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:19:06Z","timestamp":1774862346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03341-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,20]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03341-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted as a retrospective clinical audit of outcomes for patients treated for pancreatic cancer at the Clatterbridge Cancer Centre NHS Foundation Trust. All methods were performed in accordance with relevant institutional guidelines and NHS information governance requirements. Approvals for the audit were obtained from the Clinical Audit Committee at the Clatterbridge Cancer Centre NHS Foundation Trust. In line with UK Health Research Authority guidance, formal Research Ethics Committee approval was not required for this work, as it constituted a service evaluation and clinical audit. As this was a retrospective audit using routinely collected clinical data, individual informed consent to participate was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}